Possible Role of LCZ696 in Atherosclerosis: New Inroads and Perspective

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2023 Aug 1

PMID 37526794

Authors

Hayder M Al-Kuraishy

Ali I Al-Gareeb

Engy Elekhnawy

Gaber El-Saber Batiha

Affiliations

Soon will be listed here.

Abstract

LCZ696 blocks both angiotensin receptor type 1 (ATR1) and neprilysin (NEP), which are intricate in the degradation of natriuretic peptides (NPs) and other endogenous peptides. It has been shown NEP inhibitors and LCZ696 could be effectively in the management of atherosclerosis (AS). However, the underlying mechanism of LCZ696 in AS is needed to be clarified entirely. Hence, this review is directed to reconnoiter the mechanistic role of LCZ696 in AS. The anti-inflammatory role of LCZ696 is related to the inhibition of transforming growth factor beta (TGF-β)-activated kinase 1 (TAK) and nod-like receptor pyrin 3 receptor (NLRP3) inflammasome. Moreover, LCZ696, via inhibition of pro-inflammatory cytokines, oxidative stress, apoptosis and endothelial dysfunction can attenuate the development and progression of AS. In conclusion, LCZ696 could be effective in the management of AS through modulation of inflammatory and oxidative signaling. Preclinical and clinical studies are recommended in this regard.

Citing Articles

The Peripheral Amyloid-β Nexus: Connecting Alzheimer's Disease with Atherosclerosis through Shared Pathophysiological Mechanisms.

Khowdiary M, Al-Kuraishy H, Al-Gareeb A, Albuhadily A, Elhenawy A, Rashwan E Neuromolecular Med. 2025; 27(1):20.

PMID: 40032716 PMC: 11876215. DOI: 10.1007/s12017-025-08836-2.

The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword.

Zaidalkilani A, Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Al-Farga A J Cell Mol Med. 2024; 28(23):e70067.

PMID: 39663784 PMC: 11635126. DOI: 10.1111/jcmm.70067.

Pharmacological characterization of the antidiabetic drug metformin in atherosclerosis inhibition: A comprehensive insight.

Turkistani A, Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Bahaa M Immun Inflamm Dis. 2024; 12(8):e1346.

PMID: 39092773 PMC: 11295104. DOI: 10.1002/iid3.1346.

References

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D . Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019; 8(13):e012272. PMC: 6662364. DOI: 10.1161/JAHA.119.012272. View

Solomon S, McMurray J, Anand I, Ge J, Lam C, Maggioni A . Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019; 381(17):1609-1620. DOI: 10.1056/NEJMoa1908655. View

Pardossi-Piquard R, Dunys J, Yu G, St George-Hyslop P, Alves da Costa C, Checler F . Neprilysin activity and expression are controlled by nicastrin. J Neurochem. 2006; 97(4):1052-6. DOI: 10.1111/j.1471-4159.2006.03822.x. View

Bayes-Genis A, Prickett T, Richards A, Barallat J, Lupon J . Soluble neprilysin retains catalytic activity in heart failure. J Heart Lung Transplant. 2016; 35(5):684-5. DOI: 10.1016/j.healun.2015.12.015. View

Bayes-Genis A, Barallat J, Galan A, De Antonio M, Domingo M, Zamora E . Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015; 65(7):657-65. DOI: 10.1016/j.jacc.2014.11.048. View

Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J . Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail. 2016; 18(1):89-93. DOI: 10.1002/ejhf.435. View

Mishra D, Singh S, Narayan G . Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis. Mol Biol Int. 2016; 2016:4328697. PMC: 5124668. DOI: 10.1155/2016/4328697. View

Reynaud D, Lefort N, Manie E, Coulombel L, Levy Y . In vitro identification of human pro-B cells that give rise to macrophages, natural killer cells, and T cells. Blood. 2003; 101(11):4313-21. DOI: 10.1182/blood-2002-07-2085. View

10.

Visco C, Xu-Monette Z, Miranda R, Green T, Li Y, Tzankov A . Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP.... Leukemia. 2012; 26(9):2103-13. PMC: 3637886. DOI: 10.1038/leu.2012.83. View

11.

Revuelta-Lopez E, Nunez J, Gastelurrutia P, Cediel G, Januzzi J, Ibrahim N . Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. ESC Heart Fail. 2020; 7(2):559-566. PMC: 7160502. DOI: 10.1002/ehf2.12607. View

12.

Libby P . The changing landscape of atherosclerosis. Nature. 2021; 592(7855):524-533. DOI: 10.1038/s41586-021-03392-8. View

13.

Fok P, Lanzer P . Media sclerosis drives and localizes atherosclerosis in peripheral arteries. PLoS One. 2018; 13(10):e0205599. PMC: 6203409. DOI: 10.1371/journal.pone.0205599. View

14.

Roh J, Kwon B, Ihm S, Lim S, Park C, Chang K . Predictors of Significant Coronary Artery Disease in Patients with Cerebral Artery Atherosclerosis. Cerebrovasc Dis. 2019; 48(3-6):226-235. DOI: 10.1159/000504927. View

15.

Lovshin J, Bjornstad P, Lovblom L, Bai J, Lytvyn Y, Boulet G . Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care. 2018; 41(12):2570-2578. PMC: 6245210. DOI: 10.2337/dc18-1236. View

16.

Schipper H, de Ferranti S . Cardiovascular Risk Assessment and Management for Pediatricians. Pediatrics. 2022; 150(6). DOI: 10.1542/peds.2022-057957. View

17.

Vergallo R, Crea F . Atherosclerotic Plaque Healing. N Engl J Med. 2020; 383(9):846-857. DOI: 10.1056/NEJMra2000317. View

18.

Shi P, Ji H, Zhang H, Yang J, Guo R, Wang J . circANRIL reduces vascular endothelial injury, oxidative stress and inflammation in rats with coronary atherosclerosis. Exp Ther Med. 2020; 20(3):2245-2251. PMC: 7401493. DOI: 10.3892/etm.2020.8956. View

19.

Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M . The effects of oxidative stress on the development of atherosclerosis. Biol Chem. 2019; 400(6):711-732. DOI: 10.1515/hsz-2018-0397. View

20.

Hartley A, Haskard D, Khamis R . Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - Novel insights and future directions in diagnosis and therapy<sup/>. Trends Cardiovasc Med. 2018; 29(1):22-26. DOI: 10.1016/j.tcm.2018.05.010. View

21.

Ito F, Ito T . High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants (Basel). 2020; 9(5). PMC: 7278571. DOI: 10.3390/antiox9050362. View